Multiple Sclerosis Study (Relapsing
Remitting)- DUS01
The purpose of this 6-month,
randomized, open-label, multi-center study is to evaluate the
safety and tolerability of a Novartis investigational drug in in
people diagnosed with relapsing forms of multiple sclerosis (MS)
who have been on previous Disease Modifying Therapy(s) (DMT).
Trial phase: Phase 4
Participation Duration: Participants will be required to
visit the study center 6 times over 7 months.
Protocol Number: CFTY720DUS01 |
The next step is to see if you (or the participant) meet the
basic criteria required for participation in this clinical
trial. Please fill out the questionnaire below to see if you (or
the participant) may be suitable for the clinical trial.
Answers to all questions are required to determine if you
meet the preliminary qualifications for the study.
|